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Abstract
Nanog is a pivotal transcription factor in embryonic stem (ES) cells and is essential for maintaining the pluripotency and self-
renewal of ES cells. SUMOylation has been proved to regulate several stem cell markers’ function, such as Oct4 and Sox2.
Nanog is strictly regulated by Oct4/Sox2 heterodimer. However, the direct effects of SUMOylation on Nanog expression
remain unclear. In this study, we reported that SUMOylation repressed Nanog expression. Depletion of Sumo1 or its
conjugating enzyme Ubc9 increased the expression of Nanog, while high SUMOylation reduced its expression. Interestingly,
we found that SUMOylation of Oct4 and Sox2 regulated Nanog in an opposing manner. SUMOylation of Oct4 enhanced
Nanog expression, while SUMOylated Sox2 inhibited its expression. Moreover, SUMOylation of Oct4 by Pias2 or Sox2 by
Pias3 impaired the interaction between Oct4 and Sox2. Taken together, these results indicate that SUMOylation has
a negative effect on Nanog expression and provides new insights into the mechanism of SUMO modification involved in ES
cells regulation.
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Introduction
Derived from the inner cell mass (ICM) of the blastocyst, ES
cells can proliferate indefinitely in vitro and differentiate into cells
of all three germ layers. These unique properties make ES cells
exceptionally valuable for cell replacement therapies, drug
discovery and regenerative medicine [1,2]. An intricate network
of transcription factors has been found in undifferentiated ES cells
for maintaining its features. And recent studies indicated that
Nanog, a homeobox transcription factor, was involved in this
network and played a critical role in regulating the cell fate of the
pluripotent ES cells [3]. Nanog is expressed in ES cells and is
thought to be a key factor in maintaining ES cells pluripotency. It
functions together with other factors such as Oct4 and Sox2 to
establish ESC identity [4–6]. In addition, Nanog is essential for
early embryonic development, and is regarded as the gateway for
somatic cells to reprogram into induced pluripotent cells [7].
The small ubiquitin-like modifier (SUMO) proteins are
structurally similar to ubiquitin although they share less than
20% sequence identity. Like ubiquitylation, protein SUMOylation
is regulated by a cascade of reactions involving SUMO-activating
enzymes (SAE1/SAE2), conjugating enzymes (Ubc9) and multiple
E3 ligases (e.g. PIAS1, PIAS2, PIAS3, PIAS4 (PIASy), RanBP2
and Pc2) that covalently attach SUMO to specific protein
substrates. In addition, a number of de-SUMOylation enzymes
(i.e. Ulp/SENPs) for rapid deconjugation are core components of
this reversible post-translational modification [8].
In lower eukaryotes, a single SUMO gene is expressed (Smt3 in
Saccharomyces cerevisiae), whereas in vertebrates three paralogs
designated as SUMO1–3 are ubiquitously expressed in all tissues,
the human genome also encodes a gene for SUMO4 that appears
to be uniquely expressed in the spleen, lymph nodes and kidney
[9]. Ubc9 is the sole E2 enzyme for SUMOylation [10]. SUMO
E3 ligases are the enzymes assumed to ensure substrate specificity,
and most E3 ligases interact with both the SUMO-Ubc9 thioester
and substrate to bring them in close proximity for SUMO transfer
[11].
Covalent modification of proteins by small ubiquitin-like
modifiers (SUMO) cause changes in the intracellular localization
and stability of proteins, and alters their abilities to interact with
other proteins and nucleic acids. In particularly, these modifica-
tions affect the functions of proteins involved in a wide range of
cellular processes [8,12–14], including macromolecular transport,
the maintenance of nuclear structure, nucleic acid DNA metab-
olism and cell signaling.
The most well-known group of SUMO substrates is transcrip-
tion factors, in which SUMOylation regulates transcriptional
activity. Previous studies have revealed that SUMOylation can
positively or negatively regulate the transcriptional activity of
pluripotent factors such as Oct4 and Sox2, which play critical roles
in the maintenance of ES cell pluripotency and promote
reprogramming of fibroblasts [15–17], thereby linking SUMOyla-
tion with pluripotency. In vivo, the expression of Nanog is strictly
regulated by the Oct4/Sox2 heterodimer and other transcription
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39606factors [18]. To further investigate the role of SUMOylation in the
regulatory gene network of ES cells, we examined the effect of
SUMOylation on Nanog expression. Our results showed that
SUMOylation of transcription factors Sox2 and Oct4 regulates
their transcriptional activity differentially and represses Nanog
expression.
Results
SUMOylation represses Nanog expression
SUMOylation is an important post-translational protein mod-
ification and regulates many critical cellular processes. SUMOyla-
tion of Sox2 inhibited its DNA binding activity and negatively
regulated its transcriptional activity [15], while SUMOylation of
Oct4 enhanced its stability, DNA binding, and transactivation
[16,17]. These data indicated that SUMOylation plays an
important role in regulation of genes expression in ES cells. To
gain a general understanding of the potential role of SUMO
modification in ES cells, we reduced the SUMOylation level by
knockdown of Sumo1/Ubc9, or increased the SUMOylation level
by exogenously expressed Sumo1/Ubc9 in F9 embryonal carci-
noma (F9 EC) cells. Real-time quantitative PCR (qPCR) and
western blot results showed that short hairpin RNAi constructs
could efficiently reduce the expression level of Sumo1 and Ubc9
compared with that of empty vector or scramble RNAi vector
(Fig. 1A and B). Overexpression of Sumo1 and Ubc9 was detected
in HA-Sumo1 and HA-Ubc9 transfected F9 EC cells (Fig. 1C).
Under this condition, we measured the mRNA levels of key
regulators Nanog, Sox2 and Oct4, and found that Nanog transcripts
were increased by 1.5–2-fold upon knockdown of Sumo1/Ubc9
(Fig. 1D). In contrast, overexpression of Sumo1/Ubc9 reduced the
Nanog mRNA level to 20–30% compared with that of the control
(Fig. 1E). The expression level of transcription factors Sox2 and
Oct4 (Pou5f1) did not change significantly (data not shown).
Consistent with qPCR results, overexpression of Sumo1/Ubc9 led
to a dramatic reduction of Nanog protein compared with control
cells, while knockdown of Sumo1/Ubc9 increased Nanog expres-
sion (Fig. 1F). To confirm these results, F9 EC cells were treated
with ginkgolic acid, an inhibitor of SUMOylation for 10 h [19].
Then, we detected the SUMOylation level and Nanog expression
by western blot and qPCR. The result further proved that Nanog
gene expression is suppressed by SUMOylation (Fig. S1).
Dual-luciferase assays were performed to determine whether
SUMOylation repressed the transcriptional activity of the Nanog
proximal promoter. The proximal promoter sequence of Nanog
containing the Sox2/Oct4 element (2230 to +50 relative to the
transcription start site) was cloned and inserted into a pGL4.10
vector, then we cotransfected F9 EC cells with the reporter vector
and shRNA or Sumo1/Ubc9 expression constructs. As shown in
Figure 1G, low luciferase activity was observed in Sumo1/Ubc9-
overexpressing cells. However, we noted that the luciferase activity
of the Nanog proximal promoter did not increase significantly in
Sumo1/Ubc9 knockdown cells (Fig. 1G), in F9 EC cells, there still
be many other SUMO substrates except Oct4 and Sox2 (Fig. 1F),
the global reduction of SUMOylation may decreases the SUMO
modification of other protein, thereby disturbs the results. Taken
together, these results suggested that SUMOylation suppresses
Nanog expression in vivo through inhibiting the transcriptional
activity of its proximal promoter.
SUMOylation of Oct4 and Sox2 regulate Nanog by
different ways
Next, we investigated how SUMOylation suppressed Nanog
expression. Transcription factors Oct4 and Sox2 form a hetero-
dimer and bind to the Nanog promoter [18]. Moreover, Oct4 and
Sox2 have been shown to be modified by Sumo1 at Lysine 118
and lysine 247 respectively [15]. To test whether Nanog was
regulated indirectly by SUMOylation of Oct4 and Sox2, we
detected the expression patterns of Nanog in response to various
levels of SUMOylated Oct4 and Sox2.
When co-overexpressed the Flag-Tagged Oct4 and HA-Tagged
Sumo1, a high molecular mass band of a covalently modified form
of Oct4 was detected and the band intensity increased with
overexpression of Ubc9. In contrast, the modified band was rarely
found when the SUMO acceptor site in Oct4 was mutated (Oct4
K118R) (Fig. 2A). SUMOylation of Sox2 and Sox2 K247R was
also characterized. Compared with wild-type Sox2, the Sox2
K247R mutant failed to form higher molecular bands when it was
co-transfected with HA-tagged Sumo1 or Ubc9 (Fig. 3A).
Subsequently, qPCR was used to quantify the Nanog transcripts
in F9 EC cells expressing wild type Oct4 or Oct4 K118R. As
shown in Figure 2, the relative transcription level of Nanog in cells
co-expressing Oct4 and Sumo1 or Ubc9 was 1.5–2-fold higher
than in Oct4 K118R-transfected cells. Consistent with qPCR
results, the protein level of Nanog was increased by the
SUMOylation of Oct4 in pluripotent cells (Fig. 2B and C). These
results indicate that SUMOylation of Oct4 increases the
expression of Nanog.
Furthermore, we examined the effect of SUMOylation of Sox2
on Nanog expression. As shown in Figure 3, co-overexpression of
wild-type Sox2 and Sumo1/Ubc9 decreased the Nanog expression
at both mRNA level and protein levels. Accordingly, compared
with the control group, Nanog transcripts were increased by more
than 1.5-fold in Sox2 K247R-transfected cells, in which Sox2 was
not modified by Sumo1. The results of western blot confirmed that
Nanog expression was inhibited by SUMOylated Sox2 (Fig. 3B
and C). Luciferase assays showed that SUMOylation of Oct4
promoted Nanog transcription (Fig. 2D), while covalent modifi-
cation of Sox2 with Sumo1 reduced Nanog transcription (Fig. 3D).
As shown in Figures 2 and 3, we noted that cotransfection of
Oct4 K118R or Sox2 with Sumo1 and Ubc9 caused the
expression level of Nanog to fall back to the baseline level. This
effect may be due to the complexity of endogenous Oct4 and
Sox2, because the Oct4/Sox2 dimers would be altered by
manipulating either Oct4 or Sox2. To overcome this effect, we
performed additional experiments using NIH 3T3 cells that do not
express endogenous Oct4 or Sox2 (Fig. 4A). Consistent with results
using F9 EC cells, we found that SUMOylation of Oct4 promoted
transcription of the Nanog proximal promoter (Fig. 4B), and
SUMOylation of Sox2 decreased its transactivity for the Nanog
proximal promoter (Fig. 4C). However, the luciferase activity did
not fall back to the levels of the negative control, indicating that
the SUMOylation levels of both exogenous and endogenous
Oct4/Sox2 was altered by overexpression of Sumo1 and Ubc9 in
F9 EC cells.
To further verify our results, single site Octamer (Oct)/Sox
reporter assays were performed with NIH 3T3 cells and a pGL3-
promoter construct, in which three tandem repeats of the Oct/Sox
element had been introduced (Fig. 4D). Cotransfection of the
36Oct reporter construct with Flag-Oct4 led to a 2-fold increase
in luciferase activity, and the luciferase activity increased to 4–4.5
fold by cotransfecting Sumo1 and Ubc9 plasmids. In contrast, the
luciferase activity of Oct4 K118R-transfected NIH 3T3 did not
increase significantly, even with cotransfection of Sumo1 and
Ubc9 plasmids (Fig. 4E). As shown in Figure 4F, cotransfection of
the 36Sox reporter construct with Myc-Sox2 led to increased
luciferase activity by more than 1.5-fold, while luciferase activity
decreased significantly when Sumo1 and Ubc9 plasmids were
Regulation of Nanog Expression by SUMOylation
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39606Regulation of Nanog Expression by SUMOylation
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39606cotransfected. The luciferase activity of Sox2 K247R-transfected
NIH 3T3 cells did not change significantly (Fig. 4F). Taken
together, our data shows that SUMOylation of Oct4 and Sox2
regulates the Nanog proximal promoter by distinct mechanisms in
which SUMOylation of Oct4 promotes Nanog expression, while
SUMOylation of Sox2 inhibits Nanog expression.
SUMOylation of Oct4 and Sox2 does not change their
subcellular localization
It has been reported that SUMOylation modulates the function
of some proteins, such as nucleophosmin/B23 and von Hippel-
Lindau (VHL) tumor suppressor protein, by affecting their
distribution between the cytoplasm and nuclei of mammalian
cells [20,21]. To investigate whether SUMOylation regulated
Nanog expression by changing the subcellular localization of Sox2
and Oct4, red fluorescent protein (RFP)-tagged Oct4/Oct4
K118R and Sox2/Sox2 K247R were cotransfected with various
combinations of plasmids into F9 EC cells. As shown in Figure 5,
both SUMOylated Oct4/Sox2 and unmodified Oct4 K118R/
Sox2 K247R were distributed in the nucleus, suggesting that
SUMOylation of Oct4 and Sox2 did not change their subcellular
localization. Moreover, we did not observe any obvious changes in
the distribution of Oct4 and Sox2 within nucleus, by neither
enhancing nor inhibiting SUMOylation (Fig. 5). These results are
similar to those of a previous report and support that SUMOyla-
tion does not affect subcellular localization of Sox2 and Oct4 [16].
SUMOylation disrupts the interaction between Sox2 and
Oct4
Protein-protein interactions are often regulated by posttransla-
tional modifications, such as phosphorylation and SUMOylation.
SUMOylation regulates protein-protein interactions by providing
or masking protein-interacting surfaces. In ES cells, the hetero-
dimer form of Oct4 and Sox2 is required to regulate other linage
specific genes including Nanog [22,23]. In order to test the effect of
SUMOylation on the formation of Oct4-Sox2 heterodimer, co-
immunoprecipitation (CoIP) experiment were performed using
NIH 3T3 cells. As shown in Figure 6, the interaction between
wild-type Sox2 and Oct4 was decreased when they were modified
by Sumo1 compared to the interaction between unmodified Sox2
and Oct4, suggesting that SUMOylation impaired the binding
affinity between Oct4 and Sox2. In addition, the suppressive effect
of SUMOylation on Nanog expression via Oct4 and Sox2 may be
partially due to the interference of heterodimer formation of
Oct4/Sox2 by the modification of Sumo1.
SUMO E3 ligase are involved in regulating Nanog
expression
Furthermore, we tested the effect of SUMO E3 ligases on
Nanog expression. After cotransfection of NIH3T3 cells with
SUMO E3 ligases Pias1, Pias2, Pias3 and Pias4, and Oct4 or
Sox2, cell lysates were precipitated using anti-Sumo1 antibody
coated beads and analyzed by western blot. As shown in Figure 7,
Pias3, and not other PIAS family E3 ligases, enhanced Oct4
SUMOylation as indicated by the high intensity of the
SUMOylated Oct4 band was detected in sample cotransfected
with Oct4 and Pias3 plasmids (Fig. 7A). However, Pias3 did not
enhance the SUMOylation of Sox2. Instead, Pias2 was found to
function as an E3 ligase toward Sox2 and enhanced its
SUMOylation (Fig. 7B).
To explored the role of Pias2 and Pias3 in the Nanog
transcription, we transfected Pias3 into F9 EC cells and found
that Pias3 could induce the Nanog expression (Fig. 7C). As
expected, we detected significantly reduced Nanog mRNA levels in
the presence of Pias2 (Fig. 7D). Taken together, these data suggest
that SUMO E3 ligases Pias2 and Pias3 suppress or induce Nanog
expression by enhancing the SUMOylation of Sox2 or Oct4
respectively.
Discussion
To our knowledge, this is the first study to investigate the
regulation of SUMO on Nanog, a transcription factor required for
maintaining the pluripotency of ES cells. We found that
SUMOylation mediated a negative effect on Nanog expression, in
which overexpression of the key components of the SUMO system
decreased Nanog expression significantly. We also tried to
elucidate the mechanisms of SUMOylation, which regulate
Nanog. We revealed that SUMO modification of Sox2 and
Oct4 alters their transcriptional activity and interaction. Further-
more, the results showed that SUMO E3 ligases Pias2 and Pias3
are involved in regulating Nanog by enhancing SUMOylation of
Sox2 and Oct4, respectively. Taken together, our study indicates
that SUMOylation regulates Nanog by affecting transcription
factors Sox2 and Oct4.
SUMOylation is a post-translational modification involved in
various cellular processes, such as nuclear-cytosolic transport,
transcriptional regulation, apoptosis, protein stability and the
DNA damage response [24–27]. Most recently, it has been
reported that the SUMOylation pathway is involved in early
development and the cellular pluripotency of vertebrates [28–31].
Additionally, some transcription factors, which function in the
protein interaction network for the pluripotency of ES cells, are
regulated by SUMOylation. These data suggests that SUMOyla-
tion has pivotal roles in cell differentiation and the maintenance of
ES cell stemness.
Because the Nanog promoter has a Nanog consensus site
upstream of the transcription start site [32], we considered that
Sumo1 may covalently modify Nanog as a feedback response to
repress Nanog expression. We analyzed the Nanog amino acid
sequence using the SUMOsp 2.0 software [33], but no potential
SUMOylation site Y-K-X-E (where Y represents a hydrophobic
amino acid, and X represents any amino acid) was found. Next,
Figure 1. SUMOylation represses Nanog expression in F9 embryonal carcinoma cells. (A) Endogenous Sumo1 expression in control and
Sumo1-knockdown F9 EC cells. After 48 hours post-transfection with a Sumo1-specific shRNA construct (sh-Sumo1) or negative control (Vector and
sh-scramble), Sumo1 expression was determined by qPCR and western blot. (B) Endogenous Ubc9 expression in control and Ubc9-knockdown F9 EC
cells. After 48 hours post-transfection with an Ubc9-specific shRNA construct (sh-Ubc9) or negative control (Vector and sh-scramble), Ubc9 expression
was determined by qPCR and western blot. (C) Overexpression of Sumo1 and/or Ubc9 in F9 EC cells. F9 EC cells were transfected with pCMV-HA-
Sumo1, pCMV-HA-Ubc9 and empty vector as indicated, Sumo1 and Ubc9 mRNA levels were detected by qPCR respectively. (D) qPCR analysis of
Nanog expression in F9 EC cells in response to knockdown of Sumo1/Ubc9. (E) qPCR analysis of Nanog expression in F9 EC cells in response to
overexpression of Sumo1/Ubc9. (F) Endogenous Nanog protein in F9 EC cells were determined by western blot after transient transfection with the
indicated constructs. (G) Transcriptional activity of the Nanog proximal promoter in response to SUMOylation. After 48 hours post-transfection with
the indicated plasmids, luciferase activity was determined and normalized against control empty vector transfection. qPCR data were normalized to
GAPDH. Data are presented as the mean +/2 SD and are derived from three independent experiments. *, p,0.05; **, p,0.01; WB: western blot.
doi:10.1371/journal.pone.0039606.g001
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positively regulate Nanog by binding to the proximal promoter of
Nanog. However, our results showed that SUMOylation of Oct4
and Sox2 had opposing effects on Nanog expression. SUMOy-
lated Oct4 enhanced Nanog expression (Fig. 2), and conversely,
SUMOylated Sox2 downregulated Nanog expression (Fig. 3).
Additional luciferase assays demonstrated that SUMOylation
repressed Nanog transcription via modulating Oct4/Sox2 binding
to the Oct/Sox element in the Nanog proximal promoter region
(Fig. 2D, 3D and 4D). This effect might be due to the fact that
SUMOylation diminishes the DNA binding activity of Sox2, but
enhances Oct4 binding to DNA octamer element [15,16]. F9 EC
cells express endogenous Oct4 and Sox2, hence the dynamic of the
endogenous Oct4/Sox2 dimers that bind to the Nanog promoter
Figure 2. SUMOylation of Oct4 enhances Nanog expression. (A) Oct4 is modified by Sumo1 at Lysine 118. Wild-type Oct4 or the SUMO
receptor site mutant Oct4 K118R was expressed in combination with HA-Sumo1 and HA-Ubc9 in F9 EC cells. (B) qPCR analysis of Nanog mRNA in
response to various levels of SUMOylated Oct4. The levels of the transcripts were normalized against control empty vector transfection. (C) Western
blot analysis of Nanog in F9 EC cells under a varying SUMOylation status of Oct4. (D) SUMOylation of Oct4 enhances the Nanog proximal promoter
transcription. Transcriptional activities of the Nanog promoter (2230 to +50 bp relative to the transcription start site) in response to various levels of
SUMOylated Oct4 were determined by dual-luciferase reporter assays. qPCR data were normalized to GAPDH. Data are presented as the mean +/2 SD
and are derived from three independent experiments. *, p,0.05; **, p,0.01; WB: western blot.
doi:10.1371/journal.pone.0039606.g002
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exogenous Oct4/Sox2, thereby further disturbing the endogenous
effect of SUMOylation on Nanog transcription. To reduce the
complexity introduced by endogenous Oct4/Sox2, we performed
reporter assays with NIH 3T3 cells, and the results further
demonstrated that SUMOylation of Oct4 enhances its transacti-
vation, and covalent modification of Sox2 with Sumo1 decreases
the transactivation ability of the Nanog proximal promoter (Fig. 4).
Figure 3. SUMOylation of Sox2 represses Nanog expression. (A) Covalent modification of Sox2 by Sumo1 at Lysine 247. Wild-type Sox2 and
mutant Sox2 K247R were coexpressed with HA-Sumo1 and HA-Ubc9. (B) qPCR analysis of Nanog mRNA in response to various levels of SUMOylated
Sox2. (C) Western blot analysis of Nanog in F9 EC cells under a varying status of SUMOylated Sox2. (D) Covalent modification of Sox2 with Sumo1
inhibits the transcriptional activity of the Nanog proximal promoter. Transcriptional activities of the Nanog proximal promoter (2230 to +50 bp
relative to the transcription start site) in response to various levels of SUMOylated Sox2 were determined by dual-luciferase reporter assays. qPCR
data were normalized to GAPDH. Data are presented as the mean +/2 SD and are derived from three independent experiments. *, p,0.05; **,
p,0.01; WB: western blot.
doi:10.1371/journal.pone.0039606.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39606Figure 4. SUMOylation regulates transactivity of Oct4 and Sox2. (A) NIH3T3 cells lack the expression of pluripotency genes. Detection of
Oct4, Sox2 and Nanog protein expression in wild-type and Flag-Oct4 or Myc-Sox2-transfected NIH3T3 cells, F9 EC cells lysate was used as a positive
control. (B) SUMOylation of Oct4 enhances the Nanog proximal promoter transcription in NIH3T3 cells. NIH3T3 cells were transfected with the
Regulation of Nanog Expression by SUMOylation
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39606In some cases, SUMOylation modulates target protein function
by altering their subcellular or subnuclear localization [34–36]. In
this study, to determine whether SUMOylation altered the
subcellular localization of Sox2 and Oct4, we investigated the
intracellular distribution of Sox2 and Oct4 in pluripotent F9 EC
cells. The results showed that the subcellular localization of Sox2
and Oct4, which are normally localized in the nucleus, was not
affected by SUMOylation. Therefore, our findings indicate that
SUMOylation regulates the transcriptional activity of Sox2 and
Oct4 by a mechanism other than altering nuclear localization.
It is well known that Oct4 and Sox2 are necessary to maintain
the pluripotency of ES cells. In ES cells, Oct4 and Sox2 often form
the Oct4-Sox2 heterodimer to regulate the expression of Nanog and
other target genes, and an Oct4-centered transcriptional network
controls the pluripotent cell identity [37,38]. In our current study,
the effect of SUMO modification on the protein-protein in-
teraction between Oct4 and Sox2 was evaluated by CoIP and
western blot. The results demonstrated that the Oct4-Sox2
interaction (dimerization) was impaired by SUMOylation, in
which both SUMOylated Sox2 and Oct4 showed a reduced
protein-protein binding ability. Accordingly, we speculated that
the stability of Sox2 and Oct4 binding to the Nanog promoter may
be impaired by SUMOylation.
E3 ligases contribute to SUMOylation substrate specificity and
efficiency [11]. Three main subtypes of SUMO E3 ligases have
been identified: Pias proteins, RanBP2, and Pc2 [12,39,40]. In the
present study, we found that SUMO E3 ligase Pias2 promoted
SUMOylation of Sox2 and repressed Nanog transcription, while
Pias3 enhanced SUMO modification of Oct4 and enhanced its
transactivation. Hence, we hypothesize that when Sumo1 and
Ubc9 are overexpressed in F9 EC cells, the SUMOylation of
endogenous Sox2 is enhanced by specific E3 ligases such as Pias2,
indicated plasmids, and dual luciferase assays were performed at 48 hours post-transfection. (C) SUMOylation inhibits the transcriptional activity of
Sox2 in NIH3T3 cells. NIH3T3 cells were transfected with the indicated plasmids, and then dual luciferase assays were performed at 48 hours post-
transfection. (D) Schematic representation of Octamer/Sox single site reporter constructs. The construct consisted of the firefly luciferase gene driven
by the SV40 promoter and three tandem copies of the Octamer/Sox element. (E) SUMOylation of Oct4 promotes the transcriptional activity of pGL3-
36Oct. NIH3T3 cells were cotransfected with pGL3-36Oct and various combinations of plasmids, and then luciferase activity was determined at 48
hours post-transfection. (F) SUMOylation of Sox2 decreases the transcriptional activity of pGL3-36Sox. NIH3T3 cells were cotransfected with pGL3-
36Sox and various combinations of plasmids, and then luciferase activity was determined at 48 hours post-transfection. Data are presented as the
mean +/2 SD and are derived from three independent experiments. WB: western blot.
doi:10.1371/journal.pone.0039606.g004
Figure 5. SUMOylation does not alter the subcellular localization of Oct4 and Sox2. (A) Subcellular localization of Oct4 and Oct4K118R. F9
EC cells were cotransfected with red fluorescent protein tagged Oct4/Oct4 K118R plasmids and HA-Sumo1 or HA-Ubc9. There is no obvious
difference in the subcellular localization of Sumo1-modified and unmodified Oct4. (B) The distribution of Sox2 and Sox2 K247R in F9 EC cells.
Cotransfection of F9 EC cells with pDsRed-Sox2/pDsRed-Sox2 K247R and HA-Sumo1 or HA-Ubc9. Both SUMOylated Sox2 and unmodified Sox2 K247R
localize in the nuclei. Nuclei were stained with DAPI (blue). Cells were observed and photographed under a Nikon confocal microscope at 6400
magnification.
doi:10.1371/journal.pone.0039606.g005
Regulation of Nanog Expression by SUMOylation
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39606while the amount of SUMOylated Oct4 is much less than that of
Sox2 because of the specificity of E3 ligases. Under such
circumstances, Nanog expression is mainly regulated by SUMOy-
lated Sox2, thus resulting in a decreased amount of Nanog.
Nanog plays a crucial role in maintenance of the undifferen-
tiated state of mouse ES cells, and downregulation of Nanog
induces differentiation of human ES cells [41]. Although no
obvious phenotype change was observed when we overexpressed
Sumo1 and Ubc9 in F9 EC cells, based on our studies, we believe
it is possible to induce ES cell differentiation into specific cell types
by combining SUMOylation modification with small molecule
treatments.
In conclusion, our findings demonstrate that SUMOylation
represses Nanog expression. On the one hand, SUMOylation of
Sox2 inhibits its transcriptional activity and represses Nanog
transcription, while SUMOylation also disturbs the protein-
protein interaction between Oct4 and Sox2, resulting in decreased
of Nanog expression. Additionally, previous studies showed that
there are several other SUMO substrates that express specifically
in ES cells, such as SALL1 and Klf4, SUMOylation modulates
their transcriptional activity, and these genes are involved in
regulating Nanog expression [30,31,42,43]. Therefore, we spec-
ulate that SUMOylation of pluripotency factors may be an
alternative mechanism to control the Nanog level in vivo.
Furthermore, SUMO E3 ligases might be a potential regulator
involved in the regulation of Nanog expression, and further
experiments will be needed to investigate the gene expression
patterns and substrate-specificity of SUMO E3 ligases in un-
differentiated and differentiated ES cells. Identification of the
expression difference and target specificity of SUMO E3 ligases
will be helpful to further understand the role of the SUMOylation
pathway in cell-fate determination of pluripotent cells.
Figure 6. SUMOylation impairs the protein-protein interaction between Oct4 and Sox2. NIH3T3 cells were cotransfected with various
combinations of Oct4/Oct4 K118R, Sox2/Sox2 K247R, HA-Sumo1 and HA-Ubc9 expression plasmids as indicated. Cell extracts were respectively co-
immunoprecipitated with anti-Oct4 and anti-Sox2 antibody-coated affinity beads. Whole-cell lysates (input) and immunoprecipitated proteins were
separated by 12% SDS-PAGE, followed by western blot with anti-Sox2, anti-Oct4, or anti-GAPDH antibodies. Western blot images were analyzed using
Image J. (A) The protein-protein interaction between wild-type Oct4 and Sox2, the relative band intensity values of samples to controls were
presented in bar histogram. (B) The protein-protein interaction between wild-type Oct4/Sox2 and mutant Sox2 K247R/Oct4 K118R, the relative band
intensity values of samples to controls were presented in bar histogram. CoIP: co-immunoprecipitation; WB: western blot.
doi:10.1371/journal.pone.0039606.g006
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Reagents
Unless otherwise indicated, reagents were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Primary antibodies
mouse anti Flag, mouse anti Myc, mouse anti Oct4, goat anti-
Sox2, mouse anti-Sumo1 and mouse anti-GAPDH were pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). The Rabbit anti-Nanog polyclonal antibody was obtained
from Bethyl Laboratories (Montgomery, TX, USA). Anti-rabbit,
anti-mouse and anti-goat horseradish peroxidase (HRP)-conjugat-
ed secondary antibodies were obtained from the Beyotime institute
of biotechnology (Jiangsu, China).
Cell culture and transfection
All cell culture reagents were purchased from Gibco (Invitrogen,
Carlsbad, CA, USA). Sterile plastic ware was purchased from
Nunclon (Roskilde, Denmark). Mouse F9 embryonal carcinoma
(EC) cells were purchased from the cell bank of the Chinese
Academy of Sciences and maintained in 0.1% gelatin-coated
plates with Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum. NIH3T3 cells (CRL-1658,
purchased from the American Type Culture Collection) were
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum. All experimental cultures were
incubated at 37uC in a moist atmosphere of 95% air and 5%CO2.
Transfections were performed with FuGENE HD reagent (Roche,
Basel, Switzerland) according to the manufacturer’s instructions.
Construction of plasmids
The pSilencer2.1-U6 hygro plasmid (Applied Biosystems, Foster
City, CA, USA) was used for DNA vector-based shRNA
construction. Sequences of shRNA for RNAi were as follows:
Sumo1 forward: GATCCGAATCATACTGTCAAAGACTT-
CAAGACGGTCTTTGACAGTATGATTCTTTTTTGTC-
GACA; Sumo1 reverse: AGCTTGTCGACAAAAAAGAATC
ATACTGTCAAAGACCGTCTTGAAGTCTTTGACAG-
TATGATTCG; Ubc9 forward: GATCCAAGCAGAGGCCTA-
CACAATTTTTCAAGACGAAATTGTGTA
GGCCTCTGCTTTTTTTTGTCGACA; Ubc9 reverse:
AGCTTGTCGACAAAAA
AAAGCAGAGGCCTACACAATTTCGTCTT-
GAAAAATTGTGTAGGCCTCTGCTTG. Negative control se-
quences (scramble) were as follows: forward: GATCCGAAAG-
TAGAGCGCAGAACTTTCAAGACGAGTTCTGCGCTC-
Figure 7. SUMO E3 ligases PIAS proteins mediate substrates-specific SUMOylation and regulate Nanog transcription. (A and B) Pias2
and Pias3 promote SUMOylation of Oct4 and Sox2, respectively. NIH3T3 cells were transfected with various combinations of plasmids as indicated.
SUMOylated Oct4 and Sox2 was enriched by CoIP using an anti-Sumo1 antibody, and detected by western blot with anti-Oct4 and anti-Sox2
antibodies, respectively (upper panel). (C and D) Nanog transcription is up-regulated by Pias3, but down-regulated by Pias2. Transfection of F9 EC
cells with various combinations of plasmids as indicated. The levels of Nanog transcripts were normalized against GAPDH expression. Data are
presented as the mean +/2 SD and are derived from three independent experiments. *: p,0.05; **: p,0.01. CoIP: co-immunoprecipitation; WB:
western blot.
doi:10.1371/journal.pone.0039606.g007
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CAAAAAAGAAAGTAGAGCGC
AGAACTCGTCTTGAAAGTTCTGCGCTCTACTTTCG.
The Ubc9 RNAi target sequence has been reported elsewhere [44].
These sequences were cloned into the pSilencer 2.1-U6 hygro
plasmid in accordance with the manufacturer’s instructions. The
knockdown efficiency was examined by quantitative real time
PCR (qPCR) and western blot.
Full-length cDNAs encoding mouse Sumo1, Ubc9, Sox2, Pias1,
Pias2, Pias3 and Pias4 were obtained by RT-PCR of total RNA
extracted from F9 embryonal carcinoma (EC) cells. The open
reading frame (ORF) sequences of Sox2 with mutated SUMO
accepter site (Sox2 K247R) was produced by overlapping extension
PCR, then Sumo1, Ubc9, Pias1, Pias2, Pias3 and Pias4 were inserted
into a pCMV-HA plasmid. Sox2 and Sox2 K247R were inserted
into a pCMV-Myc plasmid. Sox2 and Sox2 K247R were inserted
into a pDsRed-N1 plasmid. pcDNA3-Flag-Oct4 and pcDNA3-
Flag-Oct4 K118R plasmids were a kind gift from Michael L.
Atchison (University of Pennsylvania, Philadelphia, PA, USA)
[16]. Oct4 and Oct4 K118R were amplified by PCR using the
pcDNA3-Flag-Oct4 and pcDNA3-Flag-Oct4 K118Rconstructs as
templates and then inserted into a pDsRed-N1 plasmid.
The reporter plasmid pGL4-230 Luc reporter plasmid, contain-
ing the 2230 to +50 region of the mouse Nanog promoter was
constructed by a PCR-based method. To construct single site
reporter plasmids, a synthetic oligonucleotide containing three
tandem copies of the Oct and Sox elements (36Oct: TTA-
CAGCTTCTTTTGCATTCCATGTTACAGCTTCTTTTG-
CATTCCATGTTACAGCTTCTTTTGCATTCCATG;
36Sox: TTACAGCTTCTACAATGTCCATGTTA-
CAGCTTCTACAATGTCCATGTTACAGCTTCTA-
CAATGTCCATG) were respectively cloned into a pGL3-pro-
moter vector. All constructs were confirmed by DNA sequencing.
Luciferase reporter assay
Luciferase measurements were performed with the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. F9 EC cells
were transfected with reporter constructs and various expression
vectors with FuGENE HD following the manufacturer’s protocol.
The Renilla luciferase plasmid pGL4.73 was cotransfected as an
internal control. After 48 hours post-transfection, cells were lysed
with 200 mL/well (12 well plate) 16 passive lysis buffer for
15 minutes with shaking. 20 mL of each lysate was transferred to
a 96 well plate and assayed by addition of 100 mL Luciferase Assay
Reagent and 100 mL Stop & Glo Reagent. Data were collected
with a VICTOR X5 Multilabel Plate Reader (PerkinElmer, USA).
Reverse transcription PCR (RT-PCR) and quantitative real
time PCR (qPCR)
Total RNA was isolated from F9 EC cells using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Purified RNA was reverse-transcribed using a SYBR
PrimeScriptTM RT–PCR Kit (TaKaRa, Dalian, China). Real-
time quantification of mouse Sumo1, Ubc9, Nanog, Oct4, Sox2
mRNA was performed with an ABI StepOnePlus PCR system
(Applied Biosystems, Foster City, CA, USA) using SYBR Premix
ExTaq II (TaKaRa). The comparative Ct method was used to
calculate the relative quantity of the target gene mRNA,
normalized to Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and relative to the calibrator, and was expressed as the
fold change =22DDCt [45]. The following conditions were used
for qPCR experiments: 30 seconds at 95uC, followed by 40 cycles
of 5 seconds at 95uC and 30 seconds at 60uC. Primer sequences
used for qPCR have been described elsewhere [46,47].
Co-immunoprecipitation
NIH3T3 cells were transfected with various combinations of
constructs as indicated. After 48 hours post-transfection, cells were
collected and lysed in 16 IP buffer [50 mM Tris-HCl (pH 8.0),
150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 10% glycerol,
50 mM N-ethylmaleimide and protease inhibitor cocktail (Roche)]
on ice for 20 minutes. Protein extracts were incubated overnight
with mouse anti-Oct4 or goat anti-Sox2 antibodies at 4uC
overnight on a rotator. The next day Pierce protein A/G beads
were added followed by incubation at 4uC for 3 hours. The beads
were washed twice with 16IP buffer, and then resuspended with
30 mL1 6SDS loading buffer and placed in a 95uC heat block for
5 min. The supernatant was then used for western blot assay.
Western blot analysis
For western blot, 12% acrylamide gels were used. Separated
proteins were transferred to PVDF membranes (Millipore, Bed-
ford, MA, USA) for 2.5 h at 100 V, and the membranes were
blocked in 5% non-fat milk powder/TBST for 2 hours. Then the
membranes were incubated with the primary antibody at 4uC
overnight. After being washed three times with TBST, the
membranes were incubated further with secondary antibody for
2 h. After washing three times for 10 minutes each, immunoblots
were revealed by autograph using SuperSignal west pico substrate
(Pierce/Thermo Scientific, Rockford, IL, USA). The intensity of
protein bands was quantified using Image J software.
Determination of Oct4 and Sox2 Subcellular localization
Cotransfection of F9 EC cells using red fluorescent protein-
tagged Oct4/Oct4 K118R, Sox2/Sox2 K247R with pCMV-HA-
Sumo1 or pCMV-HA-Ubc9 plasmids. 48 hours after transfection,
cells were washed three times in PBS and fixed with 4%
paraformaldehyde in PBS for 15 minutes at room temperature,
and permeablized with 0.1% Triton X-100 in PBS for 10 minutes.
Then nuclei were stained with DAPI for 10 minutes. Cells were
observed and photographed under a Nikon confocal microscope
(Nikon, Tokyo, Japan).
Statistical analysis
Data were reported as the mean 6 standard deviation (SD), and
analyzed using Student’s t-test. p values,0.05 were considered
significant.
Supporting Information
Figure S1 Effect of SUMOylation levels on Nanog
expression in F9 embryonal carcinoma cells. (A) Treat-
ment with ginkgolic acid enhances Nanog transcription. F9 EC cells
were treated with DMSO and 100 or 200 mM ginkgolic acid for
10 hours, and then qPCR was performed to examine the relative
expression of Nanog. (B) Ginkgolic acid inhibits protein SUMOyla-
tion and promotes Nanog expression in vivo. F9 EC cells were
treated with DMSO and 100 or 200 mM ginkgolic acid (100 mM
or 200 mM) for 10 hours. Cells were lysed in RIPA buffer
containing 50 mM N-ethylmaleimide, and then lysates were
separated by 10% SDS-PAGE, followed by western blot with
anti-Sumo1, anti-Nanog and anti-GAPDH antibodies respectively.
Data are presented as the mean +/2 SD and are derived from
three independent experiments. *: p,0.05;**: p,0.01. WB:
western blot. GA: ginkgolic acid.
(TIF)
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